Assessment of hepatic steatosis by controlled attenuation parameter using the M and XL probes: an individual patient data meta-analysis
David Petroff, Ph; Valentin Blank, MD; Prof Philip N Newsome, PhD; Shalimar, MD; Cosmin Sebastian Voican, PhD; Maja Thiele, PhD; Prof Victor de Lédinghen, MD; Stephan Baumeler, MD; Prof Wah Kheong Chan, PhD; Prof Gabriel Perlemuter, MD; Ana-Carolina Cardoso, MD; Prof Sandeep Aggarwal, MD; Magali Sasso, PhD; Peter J Eddowes, MD; Michael Allison, MD; Prof Emmanuel Tsochatzis, PhD; Prof Quentin M Anstee, MD; David Sheridan, MD; Jeremy F Cobbold, PhD; Prof Sylvie Naveau, MD; Monica Lupsor-Platon, MD; Prof Sebastian Mueller, MD; Prof Aleksander Krag, PhD; Marie Irles-Depe, MD; David Semela, MD; Prof Grace Lai-Hung Wong, MD; Prof Vincent Wai-Sun Wong, MD; Prof Cristiane A Villela-Nogueira, MD
Harshit Garg, MD; Prof Olivier Chazouillères, MD; Johannes Wiegand, MDThomas Karlas, MD
BackgroundDiagnostic tools for liver disease can now include estimation of the grade of hepatic steatosis (S0 to S3). Controlled attenuation parameter (CAP) is a non-invasive method for assessing hepatic steatosis that has become available for patients who are obese (FibroScan XL probe), but a consensus has not yet been reached regarding cutoffs and its diagnostic performance. We aimed to assess diagnostic properties and identify relevant covariates with use of an individual patient data meta-analysis.
MethodsWe did an individual patient data meta-analysis, in which we searched PubMed and Web of Science for studies published from database inception until April 30, 2019. Studies reporting original biopsy-controlled data of CAP for non-invasive grading of steatosis were eligible. Probe recommendation was based on automated selection, manual assessment of skin-to-liver-capsule distance, and a body-mass index (BMI) criterion. Receiver operating characteristic methods and mixed models were used to assess diagnostic properties and covariates. Patients with non-alcoholic fatty liver disease (NAFLD) were analysed separately because they are the predominant patient group when using the XL probe. This study is registered with PROSPERO, CRD42018099284.
Findings16 studies reported histology-controlled CAP including the XL probe, and individual data from 13 papers and 2346 patients were included. Patients with a mean age of 46·5 years (SD 14·5) were recruited from 20 centres in nine countries. 2283 patients had data for BMI; 673 (29%) were normal weight (BMI <25 kg/m2), 530 (23%) were overweight (BMI ≥25 to <30 kg/m2), and 1080 (47%) were obese (BMI ≥30 kg/m2). 1277 (54%) patients had NAFLD, 474 (20%) had viral hepatitis, 285 (12%) had alcohol-associated liver disease, and 310 (13%) had other liver disease aetiologies. The XL probe was recommended in 1050 patients, 930 (89%) of whom had NAFLD; among the patients with NAFLD, the areas under the curve were 0·819 (95% CI 0·769–0·869) for S0 versus S1 to S3 and 0·754 (0·720–0·787) for S0 to S1 versus S2 to S3. CAP values were independently affected by aetiology, diabetes, BMI, aspartate aminotransferase, and sex. Optimal cutoffs differed substantially across aetiologies. Risk of bias according to QUADAS-2 was low.
InterpretationCAP cutoffs varied according to cause, and can effectively recognise significant steatosis in patients with viral hepatitis. CAP cannot grade steatosis in patients with NAFLD adequately, but its value in a NAFLD screening setting needs to be studied, ideally with methods beyond the traditional histological reference standard.
The German Federal Ministry of Education and Research and Echosens.